AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BridgeBio Pharma, Inc. Director's Dealing 2020

Dec 21, 2020

30604_dirs_2020-12-21_e9f287f1-aa68-4021-b722-2f82dd7e985b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-12-18

Reporting Person: SCHELLER RICHARD H (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-18	Common Stock	S	27105	$64.9913	Disposed	109156	Direct
2020-12-18	Common Stock	S	2895	$65.7795	Disposed	106261	Direct

Footnotes

F1: Represents the weighted average sale price of the shares sold from $64.67 to $65.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a securuity holder of the Issuer, full information regarding the number of share sold at each separate price for all transactions as reported in footnotes 1 and 2.

F2: Represents the weighted average sale price of the shares sold from $65.685 to $65.95 per share.